Edinburgh, United Kingdom, 27th February 2017: Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH), is pleased to announce the appointment of Dr Mark Payton as Chief Executive Officer (CEO).
Mark brings extensive experience of growing organisations across all aspects of the biotech environment. He was formerly CEO of Oxagen Ltd and Atopix Therapeutics. He was also co-founder of Orca Pharmaceuticals. He has also previously held senior roles with companies such as GlaxoSmithKline, Glaxo Wellcome and Biogen (now Biogen Idec). He is also a Senior Adviser to The Cleveland-based Harrington Project for Discovery and Development. Commenting on this appointment Dr Liz Roper, Partner at Epidarex Capital, said:
“We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward. Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases”.
Commenting on this appointment Dr Mark Payton, CEO of Caldan Therapeutics, said:
“Having seen the strength of the existing team, the unparalleled profile of the founders in this field and the very exciting progress made to date, I am delighted to take the helm at Caldan and look forward to contributing to the successful delivery of the Company’s goals to deliver new medicines of real benefit to the ever increasing number of patients suffering from metabolic diseases”.
